HDAC9 and mantle cell lymphoma: Only a quarter of our population (24.8%—41/165) underwent up-front consolidation with ASCT; however, in this particular subgroup, we observed, in agreement with what was demonstrated by Hermine et al., that patients with MCL undergoing induction with R-HDAC-based regimens did not show an increased OS compared to patients treated with induction based on R-CHOP regimens.